Dow Up0.59% Nasdaq Up0.75%

Medivation, Inc. (MDVN)

96.91 3.64(3.90%) Sep 16, 4:00PM EDT
ProfileGet Profile for:
Medivation, Inc.
525 Market Street
36th Floor
San Francisco, CA 94105
United States - Map
Phone: 415-543-3470
Fax: 415-543-3411

Index Membership:N/A
Full Time Employees:433

Business Summary 

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Medivation, Inc.

Corporate Governance 
Medivation, Inc.’s ISS Governance QuickScore as of Sep 1, 2014 is 8. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 9; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. David T. Hung M.D., 56
Founder, Chief Exec. Officer, Pres and Exec. Director
Ms. Jennifer J. Rhodes , 44
Chief Compliance Officer, Gen. Counsel and Corp. Sec.
Dr. Lynn Seely M.D., 55
Chief Medical Officer and Sr. VP
Mrs. Dawn Graham , 61
Interim Chief Commercial Officer and Director
Mr. Rick Bierly , 58
Chief Financial Officer and Principal Accounting Officer
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders